TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05948306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Critical Patient-Centered Skin Care Protocol
Description: A patient-centered skin care protocol prepared by the researchers in accordance with the Stetler Model will be applied to the experimental group.~Sub-titles of this protocol; evaluation of risk factors, examination of the skin from head to toe, skin hygiene, examining the effects of critical illness on the skin, mobilization and re-positioning, incontinence management, maintaining nutrition, and using a support surface. For each sub-heading, application items regarding patient demands and suggestions will be added.
Study: NCT04767451

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound assessment
Description: Lead (Pb), Cadmium (Cd), Gadolinium (Gd), Arsenic (As), Mercury (Hg), Cobalt (Co), Vanadium (V), Titanium (Ti), Sulfur (S), Chromium (Cr), Silver (Ag), Molybdenum (Mo), Boron (B), Lithium (Li), and Nickel (Ni) measurements

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound assessment
Description: Lead (Pb), Cadmium (Cd), Gadolinium (Gd), Arsenic (As), Mercury (Hg), Cobalt (Co), Vanadium (V), Titanium (Ti), Sulfur (S), Chromium (Cr), Silver (Ag), Molybdenum (Mo), Boron (B), Lithium (Li), and Nickel (Ni) measurements
Study: NCT04194632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary right ventricular pacing
Description: As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
Study: NCT05856487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-2203
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203-R1
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203-R2
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203-R3
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203 Placebo
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203 Placebo
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203 Placebo
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-2203-R1 Placebo
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203-R1 Placebo
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203-R1 Placebo
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-2203-R2 Placebo
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203-R2 Placebo
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203-R2 Placebo
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-2203-R3 Placebo
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-2203-R3 Placebo
Description: Take it once daily for 8 weeks orally.
Study: NCT06085144

Intervention type: DRUG
Intervention: Galcanezumab
Description: Receiving either 120mg or 300mg injections.
Study: NCT04200729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation with PVI
Description: The intervention will be irrigation with PVI, diluted to a concentration of 1% (containing 0.1% active iodine). After removal of the appendix from the patient's abdomen and attainment of hemostasis,10 mL/kg of 1% PVI solution will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned.
Study: NCT05759910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brainphyt high dose
Description: Participants will take BrainPhyt capsules during 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo capsules during 3 months
Study: NCT04200729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control will be usual care, which is expected to vary between institutions. The only stipulation for usual care will be that surgeons do not change their usual practice during the baseline period. Some surgeons utilize intra-abdominal irrigation while others use only local irrigation. Intraabdominal irrigation is defined as intraoperative instillation of a large volume (\> 200 mL) of irrigation solution into all 4 quadrants of the abdomen. Local irrigation is defined as instillation of a small volume of liquid, typically \<50 mL, in the operative field. Intra-abdominal irrigation is utilized with the intention of preventing IAAs while local irrigation is often used to confirm hemostasis or assist with suctioning thick purulent fluid.
Study: NCT05814835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-4 mCi 68Ga/64Cu-FAPI-XT117
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-6 mCi 68Ga/64Cu-FAPI-XT117
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-8 mCi 68Ga/64Cu-FAPI-XT117
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
Study: NCT03543163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non- Pedicled Buccal Fat Pad with Coronally Advanced flap
Description: A horizontal incision of 1.5cm in long will be made at the bottom of the vestibule with the #15 blade in the region of maxillary first and second molars, depending on side of the recipient site. A curved hemostat will be used in the blunt dissection through the buccinators muscle to temporarily reposition and loose the surrounding fascia which will allow the buccal fat pad to be exposed in the oral cavity. A portion of adipose tissue equals to the required graft size will be excised with the microsurgical scissors. The grafting material will be placed on a saline-soaked gauze until its transfer to the recipient site. Finally, the patient's check will be compressed, in order to promote the closure of the wound edges then immediately close the donor site with simple 5.0 silk thread interrupted sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sub-epithelial connective tissue graft
Description: a sub- epithelial connective tissue graft is harvested from the hard palate is used to treat area with gingival recession
Study: NCT05998863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EffCaMgCit
Description: Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate.
Study: NCT05107375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent influenza virus lysis vaccine
Description: Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent influenza virus lysis vaccine
Description: Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) group
Description: One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) group
Description: One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
Study: NCT05743972

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound-guided core biopsy
Description: Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ultrasound-guided core biopsy
Description: Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.
Study: NCT04796857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody
Description: Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.
Study: NCT05099471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax; Rituximab
Description: Combination of venetoclax and rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRC
Description: Combination of Dexamethasone / Rituximab / Cyclophosphamide
Study: NCT04796857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I: dose escalation phase. Patients will oral dosage as 10mg, 20mg, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral lenalidomide as RP2D up to 6 cycles during induction phase
Study: NCT06238726

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder
Description: Shingrix messages via SMS, patient portal, email, and/or another modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Shingrix messages via SMS, patient portal, email, and/or another modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Shingrix messages via SMS, patient portal, email, and/or another modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Shingrix messages via SMS, patient portal, email, and/or another modality
Study: NCT06518226

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated MRgRT in 2 fractions
Description: 2x12 Gy with boost to GTV up to 13.5 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care: MRgRT in 5 fractions
Description: 5x7.25 Gy
Study: NCT05853900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReMMi-D Digital Therapeutic
Description: Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReMMi-D Digital Therapeutic
Description: Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.
Study: NCT05695313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnLife®
Description: It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. The OnLife supplement will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. Placebo will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily
Study: NCT04781062

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood and urine molecular analysis (Timing 0)
Description: peripheral blood and urine sample collection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood and urine molecular analysis (Timing 0)
Description: peripheral blood and urine sample collection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood and urine molecular analysis (Timing 1)
Description: peripheral blood and urine sample collection
Study: NCT05257616

Intervention type: OTHER
Group type: OTHER
Intervention: Traction Mobilization technique
Description: Traction Mobilization was given by Researcher at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again. Participant sits comfortably or leans against a chair backrest. Palms of the hands are placed on the mastoid processes of the patient's skull while pressing the elbows in a caudal direction. It was held for 5 seconds then relaxed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traction Mobilization technique with SNAGS
Description: Traction Mobilization with SNAGS were given at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again The position of the therapist is behind him or her, medial border of therapist's right thumb is used to contact the spinous process of C6 vertebrae i.e. level above the suspected painful or hypo mobile region. Therapist's left thumb reinforces his/her (right) contact thumb. Therapist fingers are gently placed along the patient's mandible or thorax. Following the treatment plane towards the eye, lift comes from the mobilizing thumb not the contact thumb. While the glide is maintained, the patient is asked to rotate his/her head towards the side of pain or hypo mobility.
Study: NCT05507177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication training programme for healthcare providers
Description: the communication training programme is specifically designed to help Dutch primary care healthcare providers facilitate adequately deprescribing cardiometabolic medication in older patients
Study: NCT06391671

Intervention type: OTHER
Intervention: Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)
Description: Saliva and feces are collected at the families home. A questionnaire is filled in by the participant (psychological) and parents (demographical and medical info). Upon consultation we are collecting anthropometric data (date of birth, length, weight, abdominal circumference, Tanner pubertal stage, etc.)

Intervention type: OTHER
Intervention: Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)
Description: Saliva and feces are collected at the families home. A questionnaire is filled in by the participant (psychological) and parents (demographical and medical info). Upon consultation we are collecting anthropometric data (date of birth, length, weight, abdominal circumference, Tanner pubertal stage, etc.)
Study: NCT05640778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib combined with aromatase inhibitors
Description: Dalpiciclib combined with letrozole or anastrozole
Study: NCT05716880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketosteril
Description: Daily dose = 1 tabl / 5 kg of ideal body weight

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Protein Diet (MPD)
Description: MPD: daily protein intake of 0.8-1.0 g/kg of ideal body weight + up to 5 g based on daily proteinuria

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium Protein Diet (MPD)
Description: MPD: daily protein intake of 0.8-1.0 g/kg of ideal body weight + up to 5 g based on daily proteinuria
Study: NCT06302907

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buffered Local anaesthesia
Description: A buffered 2% lidocaine with 1:80000 epinephrine and sodium bicarbonate 8.4% was used for one site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buffered Local anaesthesia
Description: A buffered 2% lidocaine with 1:80000 epinephrine and sodium bicarbonate 8.4% was used for one site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unbuffered Local anaesthesia
Description: an unbuffered 2% lidocaine with 1: 80000 epinephrine for the other site at the same appointment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unbuffered Local anaesthesia
Description: an unbuffered 2% lidocaine with 1: 80000 epinephrine for the other site at the same appointment.
Study: NCT05378438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbe literacy Program in the form of workshop
Description: Two to Three hours of workshop on microbe literacy will be conducted as an intervention. Workshop includes discussion on various common microorganisms causing diseases, their sources, relationship with surroundings and management. Prime focus of the session will be on management via treatments and risk reduction via vaccination.
Study: NCT05464303

Intervention type: DRUG
Intervention: Intravenous Antibodies
Description: Treatment is usually performed with sensitive third-generation cephalosporins, and medication is adjusted according to blood culture results
Study: NCT05808959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education group
Description: After the discharge training given at the clinic in the postoperative period, the participants will be given structured training on sexual health.
Study: NCT05382351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir group will receive entecavir orally once a day, 0.5mg each time, and fasting for 2h before and after taking the medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir combined with Tenofovir Amibufenamide
Description: Entecavir combined with Tenofovir Amibufenamide group will be treated with entecavir and tenofovir amibufenamide. Entecavir is administered in the same way as before. enofovir amibufenamide orally 25mg once a day with meals
Study: NCT06394713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF31907
Description: intravenous administration, once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF31907
Description: intravenous administration, once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous administration, 75mg/m2, d1, every 3 weeks
Study: NCT05407584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orevogomab+PLD
Description: PLD (40 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks (28 days)~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following PLD over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orevogomab+Paclitaxel
Description: paclitaxel (80 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks on day 1, 8, 15~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following paclitaxel over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7
Study: NCT04036708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wetting method (WTM)
Description: The wetting method is an evidence-based, simple process to remove cyanogens from cassava flour. It involves teaching women to add water to cassava flour and allow it to stand for 2 h in the sun or 5 h in the shade for the hydrogen cyanide gas to escape. Colorfully illustrated and durable laminated posters depicting the WTM were distributed to participating households. Women received this training bi-weekly for 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wetting method (WTM)
Description: The wetting method is an evidence-based, simple process to remove cyanogens from cassava flour. It involves teaching women to add water to cassava flour and allow it to stand for 2 h in the sun or 5 h in the shade for the hydrogen cyanide gas to escape. Colorfully illustrated and durable laminated posters depicting the WTM were distributed to participating households. Women received this training bi-weekly for 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers (MISC)
Description: The study team used MISC to train DRC mothers in practical day-to-day activities with their children to enhance 5 key mediational processes: 1) focusing (getting the child's attention and engaging directing them to learning experiences); 2) exciting (communicating excitement, appreciation, and affection with the learning experience); 3) expanding (making the child aware of how the learning experience transcends the present situation and can include past and future issues beyond the immediate need of the moment); 4) encouraging (emotional support to foster the child's sense of security and competence); and 5) regulating (helping to direct the child's behavior in constructive ways with a goal towards self-regulation).
Study: NCT06548919

Intervention type: DRUG
Intervention: Endocrine therapy
Description: All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.

Intervention type: DRUG
Intervention: Chemotherapy Prednisone
Description: All chemotherapy treatment regimens approved for advanced breast cancer
Study: NCT05957289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidimensional rehabilitation
Description: Multidimensional lifestyle interventions